March 1, 2012Current Opinion in Cardiology
Genetic determinants of response to cardiovascular drugs
Key result
Genetic variation continues to be validated as a determinant of variable responsiveness and toxicity to cardiovascular drugs, with early steps underway to translate these discoveries into clinical care.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform select CV drug choices; leaves open need for outcome trials before routine adoption.
PICO
P
Population
Cardiovascular disease
E
Exposure / Comparator
Genetic variation
This review highlights the growing importance of pharmacogenomics in cardiology, noting that genetic variants influencing efficacy and toxicity of drugs like clopidogrel, warfarin, and simvastatin are increasingly being incorporated into clinical care.
Cite This Study
Wells et al. (2012) conducted a review in Cardiovascular disease. Genetic variation was evaluated. Genetic variation continues to be validated as a determinant of variable responsiveness and toxicity to cardiovascular drugs, with early steps underway to translate these discoveries into clinical care.